脑池内尼卡地平预防动脉瘤性蛛网膜下腔出血迟发性脑缺血:一项对比性回顾性队列研究
该回顾性队列分析2015年1月至2022年4月收治的高改良Fisher分级动脉瘤性蛛网膜下腔出血成人患者,按脑血管痉挛管理分为脑池内尼卡地平组、脑室内尼卡地平组和对照组。脑池内尼卡地平组未观察到迟发性脑缺血(p=0.02),且行动脉内血管成形术次数少于对照组(p=0.03);鞘内尼卡地平组6个月功能预后优于对照组(p=0.04)。作者认为这些初步结果需未来前瞻性研究证实。
要点
- 脑池内尼卡地平组未观察到迟发性脑缺血(p=0.02)。
- 脑池内尼卡地平组动脉内血管成形术次数少于对照组(p=0.03)。
- 鞘内尼卡地平组6个月功能预后优于对照组(p=0.04)。
核心结论
- 鞘内给予尼卡地平可降低高改良Fisher分级动脉瘤性蛛网膜下腔出血患者的中重度脑血管痉挛相关的迟发性脑缺血发生率并改善长期功能预后。
- 本研究还显示脑池内尼卡地平相对脑室内尼卡地平具有相对获益,减少了治疗后阶段的血管成形术次数。
- 作者指出这些初步结果需未来前瞻性研究证实。
研究设计与样本
- 回顾性分析前瞻性收集的数据,纳入2015年1月至2022年4月收治的所有因高改良Fisher分级动脉瘤性蛛网膜下腔出血住院的成人患者。
- 纳入所有存在显著影像学脑血管痉挛的患者,共70例符合纳入标准。
- 按脑血管痉挛管理分为三组:脑池内尼卡地平组11例、脑室内尼卡地平组18例、未接受鞘内尼卡地平对照组41例。
主要发现
- 脑池内尼卡地平组未观察到迟发性脑缺血病例(p=0.02)。
- 脑池内尼卡地平组动脉内血管成形术次数少于对照组(p=0.03)。
- 安全性分析显示三组并发症无差异。
- 鞘内(脑室内或脑池内)尼卡地平治疗组6个月功能预后优于对照组(p=0.04)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 作者指出这些初步结果需未来前瞻性研究证实。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Intrathecal vasoactive drugs have been proposed in patients with aneurysmal subarachnoid hemorrhage (aSAH) to manage cerebral vasospasm (CV). We analyzed the efficacy of intracisternal nicardipine compared to intraventricular administration to a control group (CG) to determine its impact on delayed cerebral ischemia (DCI) and functional outcomes. Secondary outcomes included the need for intra-arterial angioplasties and the safety profile. METHODS: We performed a retrospective analysis of prospectively collected data of all adult patients admitted for a high modified Fisher grade aSAH between January 2015 and April 2022. All patients with significant radiological CV were included. Three groups of patients were defined based on the CV management: cisternal nicardipine (CN), ventricular nicardipine (VN), and no intrathecal nicardipine (control group). RESULTS: Seventy patients met the inclusion criteria. Eleven patients received intracisternal nicardipine, 18 intraventricular nicardipine, and 41 belonged to the control group. No cases of DCI were observed in the CN group (p = 0.02). Patients with intracisternal nicardipine had a reduced number of intra-arterial angioplasties when compared to the control group (p = 0.03). The safety profile analysis showed no difference in complications across the three groups. Intrathecal (ventricular or cisternal) nicardipine therapy improved functional outcomes at 6 months (p = 0.04) when compared to the control group. CONCLUSION: Administration of intrathecal nicardipine for moderate to severe CV reduces the rate of DCI and improved long-term functional outcomes in patients with high modified Fisher grade aSAH. This study also showed a relative benefit of cisternal over intraventricular nicardipine, thereby reducing the number of angioplasties performed in the post-treatment phase. However, these preliminary results should be confirmed with future prospective studies.
引用
- Vandenbulcke A, Messerer M, Garvayo Navarro M, et al. Cisternal nicardipine for prevention of delayed cerebral ischemia in aneurysmal subarachnoid hemorrhage: a comparative retrospective cohort study. Acta Neurochir (Wien). 2024. PMID: 38472426. doi:10.1007/s00701-024-06023-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。